» Articles » PMID: 10097138

RB-mediated Suppression of Spontaneous Multiple Neuroendocrine Neoplasia and Lung Metastases in Rb+/- Mice

Overview
Specialty Science
Date 1999 Mar 31
PMID 10097138
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Alterations in pathways mediated by retinoblastoma susceptibility gene (RB) product are among the most common in human cancer. Mice with a single copy of the Rb gene are shown to develop a syndrome of multiple neuroendocrine neoplasia. The earliest Rb-deficient atypical cells were identified in the intermediate and anterior lobes of the pituitary, the thyroid and parathyroid glands, and the adrenal medulla within the first 3 months of postnatal development. These cells form gross tumors with various degrees of malignancy by postnatal day 350. By age of 380 days, 84% of Rb+/- mice exhibited lung metastases from C-cell thyroid carcinomas. Expression of a human RB transgene in the Rb+/- mice suppressed carcinogenesis in all tissues studied. Of particular clinical relevance, the frequency of lung metastases also was reduced to 12% in Rb+/- mice by repeated i.v. administration of lipid-entrapped, polycation-condensed RB complementary DNA. Thus, in spite of long latency periods during which secondary alterations can accumulate, the initial loss of Rb function remains essential for tumor progression in multiple types of neuroendocrine cells. Restoration of RB function in humans may prove an effective general approach to the treatment of RB-deficient disseminated tumors.

Citing Articles

p18INK4C and BRCA1 inhibit follicular cell proliferation and dedifferentiation in thyroid cancer.

Bai F, Liu X, Zhang X, Mao Z, Wen H, Ma J Cell Cycle. 2023; 22(13):1637-1653.

PMID: 37345432 PMC: 10361144. DOI: 10.1080/15384101.2023.2225938.


RB depletion is required for the continuous growth of tumors initiated by loss of RB.

Doan A, Arand J, Gong D, Drainas A, Shue Y, Lee M PLoS Genet. 2021; 17(12):e1009941.

PMID: 34879057 PMC: 8654178. DOI: 10.1371/journal.pgen.1009941.


Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.

Maharjan C, Ear P, Tran C, Howe J, Chandrasekharan C, Quelle D Cancers (Basel). 2021; 13(20).

PMID: 34680266 PMC: 8533967. DOI: 10.3390/cancers13205117.


Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype.

Voigt E, Wallenburg M, Wollenzien H, Thompson E, Kumar K, Feiner J Mol Cancer Res. 2021; 19(12):2015-2025.

PMID: 34593608 PMC: 8642303. DOI: 10.1158/1541-7786.MCR-20-1006.


Pathological Features of Tumors of the Nervous System in Hereditary Cancer Predisposition Syndromes: A Review.

Tadros S, Kondrashov A, Namagiri S, Chowdhury A, Banasavadi-Siddegowda Y, Ray-Chaudhury A Neurosurgery. 2021; 89(3):343-363.

PMID: 33693933 PMC: 8492608. DOI: 10.1093/neuros/nyab019.


References
1.
Li S, Brisson M, He Y, Huang L . Delivery of a PCR amplified DNA fragment into cells: a model for using synthetic genes for gene therapy. Gene Ther. 1997; 4(5):449-54. DOI: 10.1038/sj.gt.3300413. View

2.
Shan B, Chang C, Jones D, Lee W . The transcription factor E2F-1 mediates the autoregulation of RB gene expression. Mol Cell Biol. 1994; 14(1):299-309. PMC: 358379. DOI: 10.1128/mcb.14.1.299-309.1994. View

3.
Harrison D, Hooper M, Armstrong J, Clarke A . Effects of heterozygosity for the Rb-1t19neo allele in the mouse. Oncogene. 1995; 10(8):1615-20. View

4.
Li S, Rizzo M, Bhattacharya S, Huang L . Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 1998; 5(7):930-7. DOI: 10.1038/sj.gt.3300683. View

5.
Riley D, Lee E, Lee W . The retinoblastoma protein: more than a tumor suppressor. Annu Rev Cell Biol. 1994; 10:1-29. DOI: 10.1146/annurev.cb.10.110194.000245. View